ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Biosynthesis of Sciadonic Acid Derived from Gymnosperms with Anti-Colitis Activity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sciadonic acid (SCA), Δ5-unsaturated fatty acid with anti-inflammatory and lipid-regulatory properties, is predominantly derived from seeds of gymnosperms. This study established a systematic engineered Yarrowia lipolytica platform for efficient SCA production and assessing the anti-colitis efficacy of SCA as a novel therapeutic lipid. First, production of eicosadienoic acid (EDA) was biosynthesized by iterative expression of endogenous polyunsaturated fatty acid desaturase and Δ9 elongase. Different Δ5 desaturases were screened to identify high-activity enzymes capable of catalyzing EDA-CoA substrates, bypassing the rate-limiting step of phosphatidylcholine (PC)-bound substrate catalysis. Further, combined with the deletion of the β-oxidation pathway, enhancement of triglyceride assembly and malonyl-CoA supply, the resulting strain overproduced 195.5 mg/L SCA in shake flasks. Under optimized bioreactor fermentation, SCA yield reached 1.2 g/L with glucose, representing the high level of SCA production reported in Y. lipolytica. Finally, SCA significantly ameliorated dextran sulfate sodium salt (DSS) -induced colitis in mice, demonstrating dose-dependent improvements in disease activity index, colon histopathology, and pro-inflammatory cytokine suppression. Overall, this work establishes an efficient microbial production platform for SCA and provides in vivo evidence supporting the anti-colitis potential of this bioactive lipid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.